Short Term Outcomes of Low Dose Liraglutide in Obese Non Diabetic Indian Subjects-A Real World Experience

Authors: Liu Y*, Yu Y, Wang K, Boles CD, November-Rider and Collins C

DOI: 10.23880/doij-16000140

Volume 1, Issue 3

Abstract

Background: The data regarding weight loss effects of liraglutide in overweight or obese Indian non-diabetic subjects is scanty. The present study aims to investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on various anthropometric and metabolic parameters in Indian obese non- diabetic patients. Methods: A total of 17 obese Indian non-diabetic patients obese (BMI >= 30 with no co-morbidity) or overweight (BMI >=27 with at least one co-morbidity), taking Liraglutide for a short term i.e. for a period of at least 12 weeks were included in this single centered retrospective study. The patients were subcutaneously injected with liraglutide once daily with a dose of 1.8 mcg. We have not included any data of subjects who were on any concomitant anti-obesity drugs. Results: Liraglutide treatment caused significant reduction of the mean body weight (from 96.33 ± 14.45 to 90 ± 13.47 to 86.25 ± 13.19, p

Keywords: Liraglutide; Non-Diabetic; Obese; Overweight

View PDF